Röchling acquires HPT Hochwertige Pharmatechnik GmbH & Co. KG

Röchling übernimmt HPT Hochwertige Pharmatechnik GmbH & Co. KG: Damit erweitert die Röchling-Gruppe ihr Angebot anspruchsvoller Hochleistungs-Kunststoffe für die Medizintechnik und bietet positive Perspektiven für den Standort in Neuhaus am Rennweg. / Röchling acquires HPT Hochwertige Pharmatechnik GmbH & Co. KG: This expands the range of sophisticated high-performance plastics from the Röchling Group for use in Life Science Industry and offers positive prospects for the location Neuhaus am Rennweg.

The Röchling Group takes over HPT Hochwertige Pharmatechnik GmbH & Co. KG in Neuhaus am Rennweg with effect of January 1, 2015. This takeover is the continuation of Röchling's strategic expansion in the field of Life Science Industry.

The HPT Hochwertige Pharmatechnik GmbH & Co. KG specialises in the production of primary packaging for the pharmaceutical and diagnostic industry. Their product range comprises bottles, canisters, jars, closures and caps as well as assembly parts made of plastics such as PE-HD, PE-LD and PP for direct contact with liquid and solid medications. HPT produces made-to-order packaging according to their customers’ specifications and offers a wide range of high-quality products from stock.

The packaging is produced through single- or multi-layer extrusion blow moulding, injection stretch blow moulding, injection blow moulding and injection moulding. Complete packages used in pharmaceutics, diagnostics and medical technology world-wide are then created in downstream processes such as sterilisation, surface decoration and assembly in class 7 clean rooms. The management system is certified according to ISO 15378, which defines the high requirements for the production of pharmaceutical packaging, as well as ISO 13485, which determines the high requirements for the production of medical products. For this reason, HPT products offer the highest possible standard of pharmaceutical hygiene, reliability and application safety.

A consistently pursued strategy

This takeover is the logical next step in Röchling's previously announced strategy of expanding the use of plastic products for the field of Life Science Industry. Röchling already offers an extensive range of materials and production for this field through its medical grade semi-finished product program by Röchling Sustaplast and Röchling Engineering Plastics as well as its injection moulding products of Röchling Oertl Kunststofftechnik and the American subsidiary Röchling Advent Tool & Mold.

Ludger Bartels, COO of the Röchling Group, Mannheim, is positive about this takeover: "Through this acquisition we will expand our range of high-quality medical technology products made from high-performance plastics and we expect synergy effects with our other locations dealing with the topic of medical technology. HPT and their customer base around the world will profit from the close cooperation in our global company network."

HPT will continue to be managed by the well-established management team led by Karl-Heinz Sladek. He views becoming part of the Röchling Group primarily as a new opportunity for his company, which generates a turnover of 33 million euros with 250 employees. "HPT will become part of a group of companies with a leading position world-wide. This presents us with excellent prospects for further growth and protecting the jobs in Neuhaus."

In the acquisition of HPT, Röchling was advised by the M&A and strategy consultation firm Contrada Partners.